Cancer-targeting antibody–drug conjugates drive dealmaking frenzy

Melanie Senior

DOI: https://doi.org/10.1038/s41587-024-02168-5

IF: 46.9

2024-02-27

Nature Biotechnology

Abstract:Improved linker technologies and broadening payload options mark a coming of age for these precision cancer therapies.

biotechnology & applied microbiology

What problem does this paper attempt to address?

Targeting cancer with antibody-drug conjugates: Promises and challenges

Alexis Q. Dean,Shen Luo,Julianne D. Twomey,Baolin Zhang

DOI: https://doi.org/10.1080/19420862.2021.1951427

2021-01-01

mAbs

Abstract:Antibody-drug conjugates (ADCs) are a rapidly expanding class of biotherapeutics that utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the U.S. Food and Drug Administration (FDA) has approved ten ADCs, namely Adcetris®, Kadcyla®, Besponsa®, Mylotarg®, Polivy®, Padcev®, Enhertu®, Trodelvy®, Blenrep®, and Zynlonta™ as monotherapy or combinational therapy for breast cancer, urothelial cancer, myeloma, acute leukemia, and lymphoma. In addition, over 80 investigational ADCs are currently being evaluated in approximately 150 active clinical trials. Despite the growing interest in ADCs, challenges remain to expand their therapeutic index (with greater efficacy and less toxicity). Recent advances in the manufacturing technology for the antibody, payload, and linker combined with new bioconjugation platforms and state-of-the-art analytical techniques are helping to shape the future development of ADCs. This review highlights the current status of marketed ADCs and those under clinical investigation with a focus on translational strategies to improve product quality, safety, and efficacy.

medicine, research & experimental
Antibody-drug conjugates: recent advances in conjugation and linker chemistries

Kyoji Tsuchikama,Zhiqiang An

DOI: https://doi.org/10.1007/s13238-016-0323-0

2016-10-14

Abstract:The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. This new antibody-based molecular platform enables selective delivery of a potent cytotoxic payload to target cancer cells, resulting in improved efficacy, reduced systemic toxicity, and preferable pharmacokinetics (PK)/pharmacodynamics (PD) and biodistribution compared to traditional chemotherapy. Boosted by the successes of FDA-approved Adcetris® and Kadcyla®, this drug class has been rapidly growing along with about 60 ADCs currently in clinical trials. In this article, we briefly review molecular aspects of each component (the antibody, payload, and linker) of ADCs, and then mainly discuss traditional and new technologies of the conjugation and linker chemistries for successful construction of clinically effective ADCs. Current efforts in the conjugation and linker chemistries will provide greater insights into molecular design and strategies for clinically effective ADCs from medicinal chemistry and pharmacology standpoints. The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

cell biology
Antibody–drug conjugates come of age in oncology

Charles Dumontet,Janice M. Reichert,Peter D. Senter,John M. Lambert,Alain Beck

DOI: https://doi.org/10.1038/s41573-023-00709-2

IF: 112.288

2023-06-13

Nature Reviews Drug Discovery

Abstract:Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the potency of highly cytotoxic agents, potentially reducing the severity of side effects by preferentially targeting their payload to the tumour site. ADCs are being increasingly used in combination with other agents, including as first-line cancer therapies. As the technology to produce these complex therapeutics has matured, many more ADCs have been approved or are in late-phase clinical trials. The diversification of antigenic targets as well as bioactive payloads is rapidly broadening the scope of tumour indications for ADCs. Moreover, novel vector protein formats as well as warheads targeting the tumour microenvironment are expected to improve the intratumour distribution or activation of ADCs, and consequently their anticancer activity for difficult-to-treat tumour types. However, toxicity remains a key issue in the development of these agents, and better understanding and management of ADC-related toxicities will be essential for further optimization. This Review provides a broad overview of the recent advances and challenges in ADC development for cancer treatment.

pharmacology & pharmacy,biotechnology & applied microbiology
Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research

Youngbo Choi,Youbeen Choi,Surin Hong

DOI: https://doi.org/10.3390/pharmaceutics16020221

IF: 6.525

2024-02-04

Pharmaceutics

Abstract:Antibody–drug conjugate (ADC) therapy, an advanced therapeutic technology comprising antibodies, chemical linkers, and cytotoxic payloads, addresses the limitations of traditional chemotherapy. This study explores key elements of ADC therapy, focusing on antibody development, linker design, and cytotoxic payload delivery. The global rise in cancer incidence has driven increased investment in anticancer agents, resulting in significant growth in the ADC therapy market. Over the past two decades, notable progress has been made, with approvals for 14 ADC treatments targeting various cancers by 2022. Diverse ADC therapies for hematologic malignancies and solid tumors have emerged, with numerous candidates currently undergoing clinical trials. Recent years have seen a noteworthy increase in ADC therapy clinical trials, marked by the initiation of numerous new therapies in 2022. Research and development, coupled with patent applications, have intensified, notably from major companies like Pfizer Inc. (New York, NY, USA), AbbVie Pharmaceuticals Inc. (USA), Regeneron Pharmaceuticals Inc. (Tarrytown, NY, USA), and Seagen Inc. (Bothell, WA, USA). While ADC therapy holds great promise in anticancer treatment, challenges persist, including premature payload release and immune-related side effects. Ongoing research and innovation are crucial for advancing ADC therapy. Future developments may include novel conjugation methods, stable linker designs, efficient payload delivery technologies, and integration with nanotechnology, driving the evolution of ADC therapy in anticancer treatment.

pharmacology & pharmacy
Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics

Eunhee G Kim,Kristine M Kim

DOI: https://doi.org/10.4062/biomolther.2015.116

Abstract:Antibody-drug conjugates utilize the antibody as a delivery vehicle for highly potent cytotoxic molecules with specificity for tumor-associated antigens for cancer therapy. Critical parameters that govern successful antibody-drug conjugate development for clinical use include the selection of the tumor target antigen, the antibody against the target, the cytotoxic molecule, the linker bridging the cytotoxic molecule and the antibody, and the conjugation chemistry used for the attachment of the cytotoxic molecule to the antibody. Advancements in these core antibody-drug conjugate technology are reflected by recent approval of Adectris(®) (anti-CD30-drug conjugate) and Kadcyla(®) (anti-HER2 drug conjugate). The potential approval of an anti-CD22 conjugate and promising new clinical data for anti-CD19 and anti-CD33 conjugates are additional advancements. Enrichment of antibody-drug conjugates with newly developed potent cytotoxic molecules and linkers are also in the pipeline for various tumor targets. However, the complexity of antibody-drug conjugate components, conjugation methods, and off-target toxicities still pose challenges for the strategic design of antibody-drug conjugates to achieve their fullest therapeutic potential. This review will discuss the emergence of clinical antibody-drug conjugates, current trends in optimization strategies, and recent study results for antibody-drug conjugates that have incorporated the latest optimization strategies. Future challenges and perspectives toward making antibody-drug conjugates more amendable for broader disease indications are also discussed.
The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads

Valentina Boni,Manish R Sharma,Amita Patnaik

DOI: https://doi.org/10.1200/EDBK_281107

Abstract:Antibody drug conjugates (ADCs) are an emerging class of therapeutics that consist of a cytotoxic agent linked covalently to an antibody, which is directed toward a specific cell surface target expressed by tumor cells and/or the microenvironment. ADCs leverage the specificity of the antibody such that it functions as a carrier to deliver the cytotoxic payload into the tumor. Four parameters are considered critical for this class of complex engineered therapeutics: target selection, antibody, cytotoxic payload, as well as conjugation and linker technology. The development of this class of drugs has proven more complex than expected. Several challenges have arisen, including a lack of true tumor antigen specificity, early release of the cytotoxic payload into the bloodstream due to linker instability, and low potency of the payload, resulting in either greater toxicity or lack of improved efficacy compared with unconjugated cytotoxics. The approval of trastuzumab emtansine in 2013 for HER2-positive breast cancer served as a proof of concept that ADCs have therapeutic application in solid tumors. Two novel ADCs have recently been approved: trastuzumab deruxtecan for HER2-positive breast cancer and enfortumab vedotin for locally advanced or metastatic urothelial cancer. Trastuzumab deruxtecan is distinguished by a unique biochemical structure with a novel cytotoxic payload, deruxtecan-a highly potent, topoisomerase I inhibitor. Enfortumab vedotin is directed toward nectin-4 and represents an example of successful and strategic target selection. This review focuses on the concepts underlying the choice of suitable targets and novel payloads, discusses specific examples of ADCs in preclinical and clinical development, and provides future directions related to this unique class of therapeutics.
Abstract PO5-27-10: Next generation antibody drug conjugates: Multi-payload conjugates targeting multiple mechanisms of cell killing

Marco Lobba,Devin Trinter,Maxwell Nguyen,Daniel Gutierrez,Samantha Brady,Chanez Symister,Andrew Lau,Richard Kendall,Saurabh Johri,Matthew Francis

DOI: https://doi.org/10.1158/1538-7445.sabcs23-po5-27-10

IF: 11.2

2024-05-02

Cancer Research

Abstract:Abstract Background: ADCs have had tremendous impact on patient outcomes in breast cancer and are rapidly moving towards second line use. However, many patients fail to respond or relapse after treatment with ADC therapies due to tumor heterogeneity and resistance to ADC payloads. Method: CatenaBio has developed a novel Multi-Payload-Conjugate (MPC) system capable of attaching distinct payloads at different sites to the same antibody, enabling the production of single-molecule targeted combination therapies with defined DAR. Results: We screened combinations of different payloads targeting several different mechanisms attached to trastuzumab at different drug-antibody ratios to optimize tumor cell killing. These targeted combination ADCs demonstrated robust killing in both HER2 high and low tumor cell lines. Conclusion: Antibody Drug Conjugates have revolutionized the treatment of high HER2 positive breast cancer. More recently advances have been made in the design of ADCs to expand indications to include HER2 low as well as HER2 negative patients. These constructs offer the next step in ADC design and allow for the combination of multiple mechanisms of action in a single MPC that are highly effective across multiple breast cancer cell lines. These molecules offer the potential to circumvent tumor resistance pathways and deliver deeper and more durable responses. Disclosures: Marco Lobba, Devin Trinter, Maxwell Nguyen, Daniel Gutierrez, Samantha Brady, Chanez Symister, Andrew Lau, Richard Kendall, and Saurabh Johri are employed by Catena Biosciences. Matthew Francis is a co-founder and advisor to Catena Biosciences. Citation Format: Marco Lobba, Devin Trinter, Maxwell Nguyen, Daniel Gutierrez, Samantha Brady, Chanez Symister, Andrew Lau, Richard Kendall, Saurabh Johri, Matthew Francis. Next generation antibody drug conjugates: Multi-payload conjugates targeting multiple mechanisms of cell killing [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO5-27-10.

oncology
Antibody‐drug conjugates: Promising and efficient tools for targeted cancer therapy

Hadi Nasiri,Zahra Valedkarimi,Leili Aghebati‐Maleki,Jafar Majidi

DOI: https://doi.org/10.1002/jcp.26435

2018-03-25

Journal of Cellular Physiology

Abstract:Over the recent decades, the use of antibody-drug conjugates (ADCs) has led to a paradigm shift in cancer chemotherapy. Antibody-based treatment of various human tumors has presented dramatic efficacy and is now one of the most promising strategies used for targeted therapy of patients with a variety of malignancies, including hematological cancers and solid tumors. Monoclonal antibodies (mAbs) are able to selectively deliver cytotoxic drugs to tumor cells, which express specific antigens on their surface, and has been suggested as a novel category of agents for use in the development of anticancer targeted therapies. In contrast to conventional treatments that cause damage to healthy tissues, ADCs use mAbs to specifically attach to antigens on the surface of target cells and deliver their cytotoxic payloads. The therapeutic success of future ADCs depends on closely choosing the target antigen, increasing the potency of the cytotoxic cargo, improving the properties of the linker, and reducing drug resistance. If appropriate solutions are presented to address these issues, ADCs will play a more important role in the development of targeted therapeutics against cancer in the next years. We review the design of ADCs, and focus on how ADCs can be exploited to overcome multiple drug resistance (MDR).

cell biology,physiology
Antibody-Drug Conjugates: The New Frontier of Chemotherapy

Sara Ponziani,Giulia Di Vittorio,Giuseppina Pitari,Anna Maria Cimini,Matteo Ardini,Roberta Gentile,Stefano Iacobelli,Gianluca Sala,Emily Capone,David J. Flavell,Rodolfo Ippoliti,Francesco Giansanti

DOI: https://doi.org/10.3390/ijms21155510

IF: 5.6

2020-07-31

International Journal of Molecular Sciences

Abstract:In recent years, antibody-drug conjugates (ADCs) have become promising antitumor agents to be used as one of the tools in personalized cancer medicine. ADCs are comprised of a drug with cytotoxic activity cross-linked to a monoclonal antibody, targeting antigens expressed at higher levels on tumor cells than on normal cells. By providing a selective targeting mechanism for cytotoxic drugs, ADCs improve the therapeutic index in clinical practice. In this review, the chemistry of ADC linker conjugation together with strategies adopted to improve antibody tolerability (by reducing antigenicity) are examined, with particular attention to ADCs approved by the regulatory agencies (the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)) for treating cancer patients. Recent developments in engineering Immunoglobulin (Ig) genes and antibody humanization have greatly reduced some of the problems of the first generation of ADCs, beset by problems, such as random coupling of the payload and immunogenicity of the antibody. ADC development and clinical use is a fast, evolving area, and will likely prove an important modality for the treatment of cancer in the near future.

biochemistry & molecular biology,chemistry, multidisciplinary
The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively

Wen‐Qian Li,Han‐Fei Guo,Ling‐Yu Li,Yong‐Fei Zhang,Jiu‐Wei Cui

DOI: https://doi.org/10.1002/cam4.4052

IF: 4.711

2021-06-24

Cancer Medicine

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Introduction</h3><p>Traditional cancer therapy has many disadvantages such as low selectivity and high toxicity of chemotherapy, as well as insufficient efficacy of targeted therapy. To enhance the cytotoxic effect and targeting ability, while reducing the toxicity of antitumor drugs, an antibody drug conjugate (ADC) was developed to deliver small molecular cytotoxic payloads directly to tumor cells by binding to specific antibodies via linkers.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Method</h3><p>By reviewing published literature and the current progress of ADCs, we aimed to summarize the basic characteristics, clinical progress, and challenges of ADCs to provide a reference for clinical practice and further research.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>ADC is a conjugate composed of three fundamental components, including monoclonal antibodies, cytotoxic payloads, and stable linkers. The mechanisms of ADC including the classical internalization pathway, antitumor activity of antibodies, bystander effect, and non-internalizing mechanism. With the development of new drugs and advances in technology, various ADCs have achieved clinical efficacy. To date, nine ADCs have received US Food and Drug Administration (FDA) approval in the field of hematologic tumors and solid tumors, which have become routine clinical treatments.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>ADC has changed traditional treatment patterns for cancer patients, which enable the same treatment for pancreatic cancer patients and promote individualized precision treatment. Further exploration of indications could focus on early-stage cancer patients and combined therapy settings. Besides, the mechanisms of drug resistance, manufacturing techniques, optimized treatment regimens, and appropriate patient selection remain the major topics.</p></section>

oncology
Editorial: The magic bullet evolution in tumor therapy: novel drug conjugates for targeted delivery

Silvia Gazzola,Ines Neundorf,Norbert Sewald

DOI: https://doi.org/10.3389/fphar.2024.1523948

IF: 5.6

2024-12-12

Frontiers in Pharmacology

Abstract:Paul Ehrlich, the Nobel laureate in Physiology of 1908 and founder of chemotherapy, introduced the concept of the "Magic Bullet" over a century ago, referring to a drug that targets disease-causing agents without harming healthy tissues. Today, this intellectual foundation turns into the development of cytotoxic compounds that can be delivered directly on the molecular aberration of a cancer patient by inserting a specific targeting unit for the recognition of tumor cells. Ligand-based drug conjugates are now abundant, typically characterized by a three-component structure consisting of a targeting unit, a linker, and a cytotoxic payload. Antibody-drug-conjugates (ADCs), Small Molecule-drug-conjugates (SMDCs) and Peptide-drug-conjugates (PDCs) are just a few of the classes investigated through the years for applying the Ehrlich's idea, which are classified in respect of the nature of the targeting unit. Every single part of the conjugates is extremely important for achieving the desired defeat of the tumor while preserving the healthy life of the rest of the organism. While significant progress has been made, we firmly believe there is still a great deal to explore in this field. The current research highlights ongoing efforts to improve the efficiency of these constructs by innovating their molecular architectures.For instance, Anna Szlachcic and colleagues developed a fibroblast growth factor receptor (FGFR)targeting peptibody ligand that combines a novel peptide epitope with the Igc-Fc (fragment crystallizable) region to enhance serum stability and reduce the limitations associated with large monoclonal antibodies (mAb) (https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.748936/full). Daniel G. Rivera's work illustrates how introducing a C14-lipid tail to bombesin, a peptide recognized by the gastrin-releasing peptide receptor (GRPR), can improve the internalization step inside cancer cells. Furthermore, the group also modified tubulysins, a family of potent inhibitors of microtubule formation, by including a thiol group as novel site of conjugation, and they demonstrated that nanomolar cytotoxicity can be maintained while expanding therapeutic options. (https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1408091/abstract). Moreover, Sudath Hapuarachchige and his team successfully conjugated the Aurora A kinase inhibitor MLN8237 as novel payload for ADCs to an anti-PSMA monoclonal antibody, creating an ADC that incorporates imaging agents for theranostic applications (https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1408091/abstract).The significance of linkers in drug conjugate research is also underscored, as they facilitate controlled release and tumor-specific delivery while reducing side effects. For example, the Silvia Gazzola and Umberto Piarulli contribution demonstrated that the incorporation of the tetrapeptide sequence Glycine-Proline-Leucine-Glycine (GPLG), linked to the self-immolative spacer para-aminobenzyl carbamate (PABC) moiety as linker in their SMDC allows for rapid activation of MMAE within cancer cells (https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1215694/full).On the other hand, the group of Hans-Georg Lerchen developed a novel class of SMDCs that target αvβ3 integrins in tumors and release their payload via an innovative enzymatic cleavage in the tumor microenvironment. These conjugates use optimized neutrophil elastase (NE) cleavable linkers to attach various therapeutic payloads, including camptothecins and CDK-9 inhibitors, allowing efficient and traceless drug release (https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1358393/full).Further contributions highlight how innovative strategies are redefining existing paradigms in the field of drug conjugates, challenging traditional therapeutic approaches. For example, immune-stimulating antibody conjugates (ISACs) are an emerging biotherapeutic class that, unlike traditional antibody-drug conjugates (ADCs), use immunostimulatory molecules as payloads rather than cytotoxins. In this context, Samuele Cazzamalli, Alberto Dal Corso and co-workers introduced an ISAC with a Valine-Citrulline (Val-Cit) linker attached to Resiquimod (R848), a potent agonist of the toll-like-receptors TLR7/TLR8, via a PABC bond. The prodrug is designed to release the payload the presence of B or under acidic conditions, and they provided important structural information for the design of new-generation ISACs with increased linker stability (https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1320524/full). Additionally, Yana K. Reshetnyak and colleagues presented pH (Low) Insertion Peptides (pHLIP), a technology that targets the low pH of tumor microenvironments, enabling the delivery of therapeutic agents to various cell types without relyi -Abstract Truncated-

pharmacology & pharmacy
How antibody–drug conjugates aim to take down cancer

Benjamin Plackett

DOI: https://doi.org/10.1038/d41586-024-01426-5

IF: 64.8

2024-05-30

Nature

Abstract:Scientists are trying to work out how to balance potency with toxicity and tackle the cost of next-generation therapeutics. Scientists are trying to work out how to balance potency with toxicity and tackle the cost of next-generation therapeutics.

multidisciplinary sciences
Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload

Aleksei Kondrashov,Surendra Sapkota,Aditya Sharma,Ivy Riano,Razelle Kurzrock,Jacob J Adashek

DOI: https://doi.org/10.3390/pharmaceutics15082160

IF: 6.525

2023-08-19

Pharmaceutics

Abstract:Antibody-drug conjugates (ADCs) are at the forefront of the drug development revolution occurring in oncology. Formed from three main components-an antibody, a linker molecule, and a cytotoxic agent ("payload"), ADCs have the unique ability to deliver cytotoxic agents to cells expressing a specific antigen, a great leap forward from traditional chemotherapeutic approaches that cause widespread effects without specificity. A variety of payloads can be used, including most frequently microtubular inhibitors (auristatins and maytansinoids), as well as topoisomerase inhibitors and alkylating agents. Finally, linkers play a critical role in the ADCs' effect, as cleavable moieties that serve as linkers impact site-specific activation as well as bystander killing effects, an upshot that is especially important in solid tumors that often express a variety of antigens. While ADCs were initially used in hematologic malignancies, their utility has been demonstrated in multiple solid tumor malignancies, including breast, gastrointestinal, lung, cervical, ovarian, and urothelial cancers. Currently, six ADCs are FDA-approved for the treatment of solid tumors: ado-trastuzumab emtansine and trastuzumab deruxtecan, both anti-HER2; enfortumab-vedotin, targeting nectin-4; sacituzuzmab govitecan, targeting Trop2; tisotumab vedotin, targeting tissue factor; and mirvetuximab soravtansine, targeting folate receptor-alpha. Although they demonstrate utility and tolerable safety profiles, ADCs may become ineffective as tumor cells undergo evolution to avoid expressing the specific antigen being targeted. Furthermore, the current cost of ADCs can be limiting their reach. Here, we review the structure and functions of ADCs, as well as ongoing clinical investigations into novel ADCs and their potential as treatments of solid malignancies.
Exploring the next generation of antibody–drug conjugates

Kyoji Tsuchikama,Yasuaki Anami,Summer Y. Y. Ha,Chisato M. Yamazaki

DOI: https://doi.org/10.1038/s41571-023-00850-2

IF: 78.8

2024-01-09

Nature Reviews Clinical Oncology

Abstract:Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full potential of this platform necessitates innovative molecular designs to tackle several clinical challenges such as drug resistance, tumour heterogeneity and treatment-related adverse effects. Several emerging ADC formats exist, including bispecific ADCs, conditionally active ADCs (also known as probody–drug conjugates), immune-stimulating ADCs, protein-degrader ADCs and dual-drug ADCs, and each offers unique capabilities for tackling these various challenges. For example, probody–drug conjugates can enhance tumour specificity, whereas bispecific ADCs and dual-drug ADCs can address resistance and heterogeneity with enhanced activity. The incorporation of immune-stimulating and protein-degrader ADCs, which have distinct mechanisms of action, into existing treatment strategies could enable multimodal cancer treatment. Despite the promising outlook, the importance of patient stratification and biomarker identification cannot be overstated for these emerging ADCs, as these factors are crucial to identify patients who are most likely to derive benefit. As we continue to deepen our understanding of tumour biology and refine ADC design, we will edge closer to developing truly effective and safe ADCs for patients with treatment-refractory cancers. In this Review, we highlight advances in each ADC component (the monoclonal antibody, payload, linker and conjugation chemistry) and provide more-detailed discussions on selected examples of emerging novel ADCs of each format, enabled by engineering of one or more of these components.

oncology
Development of antibody-drug conjugates as targeted cancer therapeutics

Yue-mei YANG,Bo-yan ZHANG,Yan LI,Bei-fen SHEN

DOI: https://doi.org/10.13220/j.cnki.jipr.2014.01.006

2014-01-01

Abstract:Targeted therapy is a promising treatment for cancer patients. Antitumor antibody drug conjugates(ADC), the new generation of antibody technology, combine the target-specificity of monoclonal antibody (mAb) and the highly active cell-killing of drugs, taking advantages of the best characteristics of both components. ADC contain three main components: antibody, linker and cytotoxics (also frequently referred as payload). Antibodies can recognize and specifically bind to the tumor-specific antigens, leading to an antibody-assisted internalization, and payload release under low pH or the action of lysosomal proteases, so as to achieve the specificity killing of cancer cells without damaging normal tissue cells. This paper reviews the emergence and development of ADC, and discusses several possible key influential factors in the development process of ADC.
Drug conjugate-based anticancer therapy - Current status and perspectives

Yuqi Yang,Shuhang Wang,Peiwen Ma,Yale Jiang,Keman Cheng,Yue Yu,Ning Jiang,Huilei Miao,Qiyu Tang,Funan Liu,Yan Zha,Ning Li

DOI: https://doi.org/10.1016/j.canlet.2022.215969

2023-01-01

Abstract:Drug conjugates are conjugates comprising a tumor-homing carrier tethered to a cytotoxic agent via a linker that are designed to deliver an ultra-toxic payload directly to the target cancer cells. This strategy has been successfully used to increase the therapeutic efficacy of cytotoxic agents and reduce their toxic side effects. Drug conjugates are being developed worldwide, with the potential to revolutionize current cancer treatment strategies. Antibody-drug conjugates (ADCs) have developed rapidly, and 14 of them have received market approval since the first approval event by the Food and Drug Administration in 2000. However, there are some limitations in the use of antibodies as carriers. Other classes of drug conjugates are emerging, such as targeted drugs conjugated with peptides (peptide-drug conjugates, PDCs) and polymers (polymer-drug conjugates, PolyDCs) with the remaining constructs similar to those of ADCs. These novel drug conjugates are gaining attention because they overcome the limitations of ADCs. This review summarizes the current state and advancements in knowledge regarding the design, constructs, and clinical efficacy of different drug conjugates.
Better safe than sorry: dual targeting antibodies for cancer immunotherapy

Katrin Schoenfeld,Julia Harwardt,Harald Kolmar

DOI: https://doi.org/10.1515/hsz-2023-0329

2024-02-02

Biological Chemistry

Abstract:Antibody-based therapies are revolutionizing cancer treatment and experience a steady increase from preclinical and clinical pipelines to market share. While the clinical success of monoclonal antibodies is frequently limited by low response rates, treatment resistance and various other factors, multispecific antibodies open up new prospects by addressing tumor complexity as well as immune response actuation potently improving safety and efficacy. Novel antibody approaches involve simultaneous binding of two antigens on one cell implying increased specificity and reduced tumor escape for dual tumor-associated antigen targeting and enhanced and durable cytotoxic effects for dual immune cell-related antigen targeting. This article reviews antibody and cell-based therapeutics for oncology with intrinsic dual targeting of either tumor cells or immune cells. As revealed in various preclinical studies and clinical trials, dual targeting molecules are promising candidates constituting the next generation of antibody drugs for fighting cancer.

biochemistry & molecular biology
Antibody-Drug Conjugates: Advancing from magic bullet to biological missile

Ana Carolina. Veneziani,Suku Sneha,Amit M. Oza

DOI: https://doi.org/10.1158/1078-0432.ccr-23-3414

IF: 13.801

2024-02-03

Clinical Cancer Research

Abstract:Precision drug development is focusing on targeting tumor cell surface proteins for therapeutic delivery, maximizing biomarker identified on-target damage to the tumor while minimizing toxicity. A recent article demonstrated high expression of B7-H4 antigen on resistant ovarian cancer cells and described preclinical activity of B7-H4-directed antibody-drug conjugate.

oncology
Antibody-Drug Conjugates: A promising breakthrough in cancer therapy

Swapnali Parit,Ajit Manchare,Amol D Gholap,Prashant Mundhe,Navnath Hatvate,Satish Rojekar,Vandana Patravale

DOI: https://doi.org/10.1016/j.ijpharm.2024.124211

2024-06-25

Abstract:Antibody-drug conjugates (ADCs) provide effective cancer treatment through the selective delivery of cytotoxic payloads to the cancer cells. They offer unparalleled precision and specificity in directing drugs to cancer cells while minimizing off-target effects. Despite several advantages, there is a requirement for innovations in the molecular design of ADC owing to drug resistance, cancer heterogeneity along the adverse effects of treatment. The review critically analyses ADC function mechanisms, unraveling the intricate interplay between antibodies, linkers, and payloads in facilitating targeted drug delivery to cancer cells. The article also highlights notable advancements in antibody engineering, which aid in creating highly selective and potent ADCs. Additionally, the review details significant progress in clinical ADC development with an in-depth examination of pivotal trials and approved formulations. Antibody Drug Conjugates (ADCs) are a ground-breaking approach to targeted drug delivery, especially in cancer treatment. They offer unparalleled precision and specificity in directing drugs to cancer cells while minimizing off-target effects. This review provides a comprehensive examination of the current state of ADC development, covering their design, mechanisms of action, and clinical applications. The article emphasizes the need for greater precision in drug delivery and explains why ADCs are necessary.
Antibody drug conjugate: the “biological missile” for targeted cancer therapy

Zhiwen Fu,Shijun Li,Sifei Han,Chen Shi,Yu Zhang

DOI: https://doi.org/10.1038/s41392-022-00947-7

IF: 39.3

2022-03-22

Signal Transduction and Targeted Therapy

Abstract:Abstract Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker. It combines both the advantages of highly specific targeting ability and highly potent killing effect to achieve accurate and efficient elimination of cancer cells, which has become one of the hotspots for the research and development of anticancer drugs. Since the first ADC, Mylotarg ® (gemtuzumab ozogamicin), was approved in 2000 by the US Food and Drug Administration (FDA), there have been 14 ADCs received market approval so far worldwide. Moreover, over 100 ADC candidates have been investigated in clinical stages at present. This kind of new anti-cancer drugs, known as “biological missiles”, is leading a new era of targeted cancer therapy. Herein, we conducted a review of the history and general mechanism of action of ADCs, and then briefly discussed the molecular aspects of key components of ADCs and the mechanisms by which these key factors influence the activities of ADCs. Moreover, we also reviewed the approved ADCs and other promising candidates in phase-3 clinical trials and discuss the current challenges and future perspectives for the development of next generations, which provide insights for the research and development of novel cancer therapeutics using ADCs.

biochemistry & molecular biology,cell biology

Cancer-targeting antibody–drug conjugates drive dealmaking frenzy

Targeting cancer with antibody-drug conjugates: Promises and challenges

Antibody-drug conjugates: recent advances in conjugation and linker chemistries

Antibody–drug conjugates come of age in oncology

Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research

Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics

The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads

Abstract PO5-27-10: Next generation antibody drug conjugates: Multi-payload conjugates targeting multiple mechanisms of cell killing

Antibody‐drug conjugates: Promising and efficient tools for targeted cancer therapy

Antibody-Drug Conjugates: The New Frontier of Chemotherapy

The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively

Editorial: The magic bullet evolution in tumor therapy: novel drug conjugates for targeted delivery

How antibody–drug conjugates aim to take down cancer

Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload

Exploring the next generation of antibody–drug conjugates

Development of antibody-drug conjugates as targeted cancer therapeutics

Drug conjugate-based anticancer therapy - Current status and perspectives

Better safe than sorry: dual targeting antibodies for cancer immunotherapy

Antibody-Drug Conjugates: Advancing from magic bullet to biological missile

Antibody-Drug Conjugates: A promising breakthrough in cancer therapy

Antibody drug conjugate: the “biological missile” for targeted cancer therapy